Your session is about to expire
← Back to Search
Other
Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
Phase 1
Waitlist Available
Led By Blanchard
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new drug called DZD9008 with a small amount of radioactivity to see how it moves through the body. Healthy male subjects take the drug, and researchers analyze their blood, urine, and feces to understand how the drug is processed.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: [14C]-DZD9008Experimental Treatment1 Intervention
A Single dose of \[14C\]-DZD9008
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[14C]-DZD9008
2021
Completed Phase 1
~10
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Dizal PharmaceuticalsLead Sponsor
25 Previous Clinical Trials
2,877 Total Patients Enrolled
BlanchardPrincipal InvestigatorCovance